Preclinical

The TIDES USA program features concurrent tracks covering the following 6 scientific themes including in-depth development strategies, trends, and technologies across the entire spectrum of oligonucleotides, peptides, mRNA, and genome editing. Your registration provides access to the presentations across all 4 tracks, allowing you to create your own customized agenda. Each year, TIDES’ scientific agenda includes 150+ of the industry’s top scientists to present the latest science and industry updates across the entire spectrum from discovery, preclinical, clinical development through CMC, Manufacturing and commercialization of therapeutics and vaccines for oligos, peptides, mRNA and genome editing products. 

With our core focus on cell and gene therapy translation, the ISCT Annual Meeting takes an integrative approach across ALL stakeholders to address key topics spanning translational research and preclinical development through to clinical trials, regulatory approvals, commercialization and ultimately patient access.  Topics are curated to addresses the biggest bottlenecks in cell and gene therapy development.

Engage in scientific discussions on the latest tools and technologies for accelerated NK-based cellular immunotherapy development. Benefit from exclusive insights from global influencers in NK based cell therapy, addressing strategies for safety, quality control and off-target activity assessment, with the goal to fast track to clinic.

A thorough 2 day event addressing emerging strategies for the drug development of Neuroscience and successful approaches for more targeted, precise, and transformative therapies to neurodegenerative and neuropsychiatric diseases. This in-depth event will detail the journey of neuroscience discovery from initial lead through to clinical trials, bringing together leading companies for discussion, knowledge-sharing.

The triennial World Parkinson Congresses provide an international forum for basic scientists, clinical researchers, health care professionals, people with Parkinson’s and others to come together under one roof to discuss, learn, and engage in debate around the latest scientific discoveries, medical and comprehensive care practices related to Parkinson’s disease.

Uncover how companies are furthering their understanding of the tumour microenvironment through the latest technologies, including spatial imaging and novel biomarkers. Gain insights in emerging therapeutic opportunities through targeting the tumour microenvironment with immunooncology.

Immuno-Oncology (IO) 360° takes a strategic look at the business and scientific aspects of Immuno-Oncology.  With significant in-put from Lead Advisors Dr. Axel Hoos (former CEO of Scorpion Therapeutics) and Dr. James Gulley (NCI,) the conference examines the current landscape, and reports on the latest advancements in IO to improve and accelerate clinical trials. The audience is comprised of roughly 500 top executives at Pharma companies and Biotechs, as well as the financial community, consultants and leading research organizations in the field of Immuno-Oncology.  

The Gene Therapy for Ophthalmic Disorders meeting is bringing you even more world class content, bringing you two tracks of learning to tackle the pressing challenges faced in the pre-clinical stages and in clinical development. This includes challenges faces with drug targets including wet AMD, dry AMD, DME, IRDs and more.

Returning in 2022, the Tumor Myeloid-Directed Therapeutics Summit is the only industry-focused meeting dedicated to unlocking novel therapeutic potential through the myeloid compartment.  This is your ultimate forum to identify, validate, and clinically progress myeloid targets to expand the oncologists toolkit and realize better responses by engaging myeloid anti-tumor function. Designed for experts working directly on myeloid-directed therapies, and those in adjacent immuno-oncology fields, from cell therapy to checkpoint and engager development. If you’re scratching your head in attempt to enhance efficacy in solid tumors and overcome barriers in the microenvironment, this is your 500-foot view of the intricate pathways, interactions, and novel target development in the tumor microenvironment. Deep-dive into myeloid biology, guided by 27+ industry Gurus from the likes of Pionyr Immunotherapeutics, Gilead Sciences, Merck, Verseau Therapeutics, Carisma Therapeutics, Pfizer and many more. With targets such as TREM1 and TREM2 making waves in the clinic, analysis of CD47 candidates back-translating to next-generation therapies, and novel dendritic cell candidates such as FTL3 in development, this 3-day myeloid extravaganza is unmissable for anyone looking to unlock better therapeutic potential through the myeloid compartment.

As Biopharma turn their focus to autoimmune drug development, there has been an explosion of interest and investment into Treg directed therapies. Promising proof-of-concept data and early clinical read outs have fueled further hype, and the industry now looks to demonstrate efficacy. The 4th Treg Directed Therapies Summit returns to Boston this May, bigger and better than ever before, boasting 2 tracks of unparalleled content to cater to cell-based, and non-cell-based experts alike. This is the only industry-focused meeting designed to bridge the gap between early discovery through clinical development of cell-based and non cell-based Treg directed therapies to provide efficacious treatments for patients globally. With 3 days of unrivalled content spanning the fundamental biology of Tregs, optimizing early drug development, and streamlining clinical development, join with your team to:Optimize stable expansion of Tregs to maintain function to elicit durable responses
Decode Treg interactions to optimize the mechanism of actions and inform biomarker development
Rationalize activation, formulation & delivery strategy to induce antigen specific tolerance
Supercharge CMC strategy to drive the modulation of antigen-specific responses to yield maximum clinical efficacy